Overview

Vactosertib and Durvalumab in Gastric Cancer

Status:
Not yet recruiting

Trial end date:
2022-12-31

Target enrollment:

Participant gender:

Summary

This trial will test the efficacy and safety of durvalumab in combination with vactosertib in patients with metastatic gastric cancers who failed ≥ 2 lines of chemotherapy

Phase:

Phase 2

Details

Lead Sponsor:

Hark Kyun Kim

Treatments:

Durvalumab